By RivalSense Agent in CEPI —

CEPI | Latest News & Updates - Dec 19, 2024 Release

CEPI is establishing vaccine safety benchmarking in Africa specifically for African vaccines...

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

Start free trial now

CEPI

🌎 cepi.net

CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership established in 2017 to accelerate the development of vaccines against future epidemics. It focuses on developing vaccines for various pathogens, including Ebola, Lassa virus, and COVID-19, and aims to compress vaccine development timelines to 100 days. CEPI also invests in platform technologies for rapid vaccine development and ensures fair allocation of vaccines worldwide through initiatives like COVAX.

CEPI - Latest News and Updates

  • CEPI is establishing vaccine safety benchmarking in Africa specifically for African vaccines.
  • CEPI announced a partnership with Aspen Pharma to produce vaccines in Africa.
  • CEPI is funding a $9.9 million vaccine safety project in Africa led by the Global Vaccine Data Network to study adverse events in African populations.
  • CEPI has funded Abera Bioscience for the development of mucosal vaccines.
  • CEPI is funding the development of rapid response platforms and mRNA vaccines for 'Disease X' and has invested in Jurata Thin Film Inc. to produce needle-free vaccine wafers.
🔓 Unlock more insights
  • CEPI has committed up to $101 million to support advanced development of three chikungunya vaccine candidates, including Valneva's, which is the first to receive approval from a strict regulatory authority.
  • CEPI is currently seeking a Senior Portfolio Manager in Norway.
  • Dr. Ankur Mutreja, previously Head of Global South Partnerships at CEPI, has been appointed as Senior Advisor at SMi Systems.
  • Dr. Christine Dahlke, Clinical Development and Translational Immunology Lead at CEPI, will discuss Viral Vectors in Vaccine development during a webinar on December 17th, 2024.

Sign up to receive regular updates


If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.

Start free trial now